Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Teclistamab induced rapid and deep hematologic response in relapsed/refractory light chain amyloidosis: A multicenter retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

LZLiye ZhongCSChunyan Sun

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals teclistamab improves outcomes in relapsed light chain amyloidosis, indicating reduced adverse events.

Key Points

  • Teclistamab rapidly induced significant hematologic response in relapsed light chain amyloidosis patients.
  • The median time to stringent dFLC remission was 19 days, with 12 patients stabilizing during treatment.
  • The analysis included patients treated with teclistamab via subcutaneous administration after daratumumab therapy.
  • The findings suggest a feasible approach to managing adverse events such as pulmonary infections.

Cite This Study

Zhong et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6a9https://doi.org/10.1182/blood-2025-7492
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis2025
  2. 2Low-dose teclistamab in newly diagnosed multiple myeloma patients2025 · 1 citations
  3. 3Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis2025
  4. 4A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a2025 · 12 citations
  5. 5Real-world efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: Results from 87 patients treated by the polish myeloma group2025